美国制药公司艾伯维公布第二季度业绩，营收同比增长6.6%至154.2亿美元，高于分析师预期的150.3亿美元；调整后每股收益2.97美元，亦高于分析师预期的2.88美元。期内，免疫疾病治疗药物Humira的全球销售额下降58%至11.8亿美元，在美国的降幅更大。新关节炎药物Skyrizi销售强劲，全球销售额飙升62%至44.2亿美元。艾伯维预计今年调整后每股收益将在11.88至12.08美元之间，之前预期为11.67至11.87美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.